Publishing individual patient data from trials: EMA considering how and when
This article was originally published in SRA
The European Medicines Agency's policy on proactive publication of clinical trial data, which currently pertains to clinical study reports from approved drugs, will eventually be expanded to allow access to individual patient data.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.